The event featured Ekaterina Zaharieva, a key member of the European Commission. She outlined Europe’s strategic priorities in innovation, including advanced technology commercialization, regulatory frameworks, venture capital expansion, and cross-border collaboration, highlighting a more integrated European innovation ecosystem.

Previously, Kevin Xu met with António Costa, recognizing the EU’s sustained investment in science and innovation and its role in fostering global collaboration.

As a long-term partner of the Bay Area Council, MEBO Group continues to expand its global footprint. Through initiatives such as the Clinton Global Initiative “Mending European,” the company has established training networks and medical cooperation platforms across multiple European countries, advancing regenerative medicine and improving clinical capabilities.

MEBO’s participation underscores its commitment to global engagement and cross-sector collaboration, further strengthening transatlantic partnerships and innovation-driven development.

About MEBO

Founded in 1987 by Professor Rongxiang Xu, a distinguished Chinese life scientist, MEBO Group is a multinational headquartered in both China and the USA. It integrates research, development, and sales across the pharmaceuticals, medical devices, health foods, and cosmetics sectors.

At its core, MEBO focuses on regenerative life sciences, innovating with over 100 patents and more than ten joint research bases to enhance and enable the body's own regenerative abilities.

As a leader in regenerative life science, MEBO's extensive research facilities and products impact over 100 countries globally, pioneering new frontiers in the regenerative life world.